Cardiff Oncology, Inc. (CRDF) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Cardiff Oncology, Inc. is a clinical-stage biotechnology company developing novel therapies based on Polo-like Kinase 1 (PLK1) inhibition. The company's lead asset is onvansertib, an oral PLK1 inhibitor being evaluated in combination with standard-of-care therapeutics for indications including RAS-mutated metastatic colorectal cancer (mCRC), metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple-negative breast cancer (TNBC).
Key Financial Metrics
| Metric (in thousands) | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Royalty Revenues | $163 | $108 | $368 | $191 |
| Net Loss | $(11,778) | $(11,150) | $(21,789) | $(22,373) |
| Net Loss Per Share (Basic/Diluted) | $(0.26) | $(0.25) | $(0.49) | $(0.50) |
| Operating Expenses | $12,708 | $12,316 | $23,846 | $24,451 |
| Cash & Cash Equivalents | $25,501 | $19,369 | $25,501 | $19,369 |
| Short-term Investments | $34,818 | $53,168 | $34,818 | $53,168 |
| Total Liquidity (Cash + Investments) | $60,319 | $72,537 | $60,319 | $72,537 |
| Net Cash Used in Operating Activities | Not provided for Q2 | Not provided for Q2 | $(16,970) | $(15,791) |
Note: The filing does not provide a specific debt figure; total liabilities are $13.7 million, primarily consisting of accounts payable, accrued liabilities, and operating lease liabilities.
Material Changes vs. Prior Period
- Revenue Growth: Royalty revenues increased 51% year-over-year for the quarter ($163k vs $108k) and 93% year-over-year for the six months ($368k vs $191k). These revenues are derived from legacy intellectual property licenses unrelated to onvansertib.
- Expense Management: Selling, general, and administrative (SG&A) expenses decreased by $1.1 million for the quarter and $1.0 million for the six months compared to the prior year. This reduction was driven by lower salaries (due to a severance agreement expensed in the prior period) and reduced stock-based compensation.
- R&D Spend: Research and development expenses increased by $1.5 million for the quarter, primarily due to costs associated with clinical programs and increased headcount (19% growth in R&D average headcount).
- Liquidity Position: Total cash, cash equivalents, and short-term investments decreased from $72.5 million at June 30, 2023, to $60.3 million at June 30, 2024, reflecting operating cash burn partially offset by financing activities.
Guidance, Outlook, and Risks
- Clinical Outlook: The company anticipates releasing initial data from the CRDF-004 Phase 2 trial (first-line RAS-mutated mCRC) in the second half of 2024. Contingent on these results, the company plans to initiate CRDF-005, a Phase 3 registrational trial.
- Liquidity Runway: Management believes current resources ($60.3 million) are sufficient to meet funding requirements for at least the next 12 months and fund operations through the end of the third quarter of 2025.
- Capital Needs: The company expects to continue incurring losses and will require additional capital to advance clinical programs. Future equity issuances may result in shareholder dilution.
- Legal Proceedings: A class action lawsuit regarding voting standards and director elections was filed in June 2024. The plaintiff dismissed the complaint with prejudice on June 26, 2024, though the court retains jurisdiction to determine attorney's fees, which are not expected to be material.
- Subsequent Events: Between July 1 and August 6, 2024, the company sold 0.9 million shares of common stock for gross proceeds of $2.3 million.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $17.0 million operating cash outflow over the last six months against the $60.3 million liquidity position.
- CRDF-004 Trial Data: Monitor the release of initial data from the CRDF-004 Phase 2 trial in H2 2024, as this is the primary catalyst for potential Phase 3 advancement.
- Revenue Source: Confirm that royalty revenues remain non-core and unrelated to the lead drug candidate, onvansertib.
- Dilution Risk: Assess the impact of recent and potential future equity sales (e.g., the $2.3 million subsequent sale) on share count and per-share value.
- Legal Fees: Track any final determination of attorney's fees related to the dismissed class action lawsuit.